ストックスクリーナーアプリを入手
7.95
10.57%
-0.94
アフターアワーズ：
8.10
0.15
+1.89%
前日終値:
$8.89
開ける：
$8.91
24時間の取引高:
205.99K
Relative Volume:
0.07
時価総額：
$12.59M
収益：
$74,000
当期純損益:
$-13.43M
株価収益率:
-0.8457
EPS:
-9.4
ネットキャッシュフロー:
$-10.54M
1週間 パフォーマンス:
-9.45%
1か月 パフォーマンス:
-35.52%
6か月 パフォーマンス:
+33.68%
1年 パフォーマンス:
-62.36%
1日の値動き範囲:
$7.825
$9.40
1週間の範囲:
$7.825
$9.53
52週間の値動き範囲:
$0.215
$39.84
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
名前
Cyclacel Pharmaceuticals Inc
セクター
電話
908-517-7330
住所
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
CYCC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CYCC
Cyclacel Pharmaceuticals Inc
|
7.95 | 14.14M | 74,000 | -13.43M | -10.54M | -9.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
| 2020-04-27 | 再開されました | ROTH Capital | Buy |
| 2018-09-07 | 開始されました | Ladenburg Thalmann | Buy |
| 2015-10-16 | 開始されました | H.C. Wainwright | Buy |
| 2010-02-04 | 開始されました | Roth Capital | Buy |
| 2009-10-28 | 開始されました | Merriman | Buy |
| 2008-08-12 | 開始されました | Piper Jaffray | Buy |
| 2008-03-12 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2008-03-12 | 繰り返されました | Collins Stewart | Buy |
| 2008-03-12 | 繰り返されました | Needham & Co | Buy |
| 2007-11-27 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2007-08-10 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2007-06-04 | 繰り返されました | Needham & Co | Buy |
| 2007-04-23 | 開始されました | Lazard Capital | Buy |
| 2007-04-10 | 開始されました | Cantor Fitzgerald | Buy |
すべてを表示
Cyclacel Pharmaceuticals Inc (CYCC) 最新ニュース
Is Cyclacel Pharmaceuticals Inc. stock forming a cup and handleTrade Risk Report & Fast Entry Momentum Trade Alerts - newsyoung.net
Cyclacel Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Cyclacel Pharmaceuticals Implements Reverse Stock Split in July - MSN
Cyclacel Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Cyclacel reports Q2 financials, declares $0.15/share dividend. - AInvest
Cyclacel Pharmaceuticals, Inc. Reports Second Quarter 2025 Financial Results and Business Developments - Quiver Quantitative
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update - The Manila Times
Cyclacel Pharmaceuticals Slashes Losses to $1.3M, Plans Strategic Malaysian Expansion - Stock Titan
Cyclacel Pharmaceuticals files audited Q1 financials to support S-3 eligibility - Investing.com Nigeria
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock - The Globe and Mail
What makes Cyclacel Pharmaceuticals Inc. stock price move sharplyFree Momentum Stock List - thegnnews.com
Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors - The Globe and Mail
Cyclacel Stock Surges 50% After Amending Exchange Agreement with FITTERS - MSN
Cyclacel (CYCC) Stock Sees Strong Pre-Market Performance After New Study Results - 富途牛牛
Cyclacel Pharmaceuticals Inc. (CYCC) Soars 34.86% on Encouraging Preclinical Results - AInvest
Cyclacel Pharmaceuticals Stock Up 34.6% In Massive After-Hours Rally - Benzinga
Major Shareholder Cashes Out on Cyclacel Pharmaceuticals Stock! - TipRanks
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB - The Manila Times
Cyclacel Pharmaceuticals Highlights Promising Preclinical Study on Plogosertib for Treating Biliary Tract Cancer - Quiver Quantitative
Breakthrough: Novel Drug Plogosertib Effectively Targets Aggressive Biliary Cancer, Study Reveals Key Biomarker - Stock Titan
WeightWatchers Reschedules Second Quarter 2025 Earnings Release and Conference Call to Finalize Fresh Start Accounting Adoption in Connection with Emergence - The Globe and Mail
What are the technical indicators suggesting about Cyclacel Pharmaceuticals Inc.Tap into rapid wealth building techniques - Jammu Links News
What are analysts’ price targets for Cyclacel Pharmaceuticals Inc. in the next 12 monthsInvest in stocks with strong fundamentals - Jammu Links News
Is Cyclacel Pharmaceuticals Inc. stock overvalued or undervaluedAchieve breakthrough gains with expert advice - Jammu Links News
What are Cyclacel Pharmaceuticals Inc. company’s key revenue driversDynamic investment opportunities - Jammu Links News
How volatile is Cyclacel Pharmaceuticals Inc. stock compared to the marketAchieve breakthrough gains with smart trades - Jammu Links News
How does Cyclacel Pharmaceuticals Inc. compare to its industry peersUnlock powerful trading tools for investors - Jammu Links News
What is the dividend policy of Cyclacel Pharmaceuticals Inc. stockInvest smarter with actionable stock recommendations - Jammu Links News
What institutional investors are buying Cyclacel Pharmaceuticals Inc. stockHigh-yield investments - Jammu Links News
What drives Cyclacel Pharmaceuticals Inc. stock priceCapitalize on stocks with high profit margins - Jammu Links News
Should I hold or sell Cyclacel Pharmaceuticals Inc. stock in 2025Maximize returns with timely market signals - Jammu Links News
When is Cyclacel Pharmaceuticals Inc. stock expected to show significant growthAchieve breakthrough profits with smart strategies - Jammu Links News
What is the risk reward ratio of investing in Cyclacel Pharmaceuticals Inc. stockGet real-time alerts on top stocks - Jammu Links News
Cyclacel Pharmaceuticals Inc. Stock Analysis and ForecastAchieve consistent profits with smart trading - Jammu Links News
What are the latest earnings results for Cyclacel Pharmaceuticals Inc.Unprecedented growth rates - Jammu Links News
What is Cyclacel Pharmaceuticals Inc. company’s growth strategyGame-changing returns - Jammu Links News
Published on: 2025-08-03 02:26:26 - Jammu Links News
3 Artificial Intelligence (AI) Stocks That Could Make You a Millionaire - The Globe and Mail
MELI Set to Report Q2 earnings: Time to Hold or Fold the Stock? - The Globe and Mail
Is it the right time to buy Cyclacel Pharmaceuticals Inc. stockStock Strategy Recommendation For Every Investor - jammulinksnews.com
IBM Report: Canadians' Data Security Under Increased Threat, While Breach Costs Surge - The Globe and Mail
Using Python tools to backtest Cyclacel Pharmaceuticals Inc. strategiesMomentum Trading Guide with Safety Limits - Newser
What Technical Tools Say About Cyclacel Pharmaceuticals Inc. RecoveryFast Entry High Potential Stock Alerts Triggered - metal.it
Verisign’s Earnings Call: Strong Growth Amid Caution - The Globe and Mail
Celestica Beats Q2 Earnings Estimates on Solid Top-Line Growth - The Globe and Mail
How high can Cyclacel Pharmaceuticals Inc. stock goAI Trade Signal Forecast with Chart Logic - Newser
Custom strategy builders for tracking Cyclacel Pharmaceuticals Inc.Free Daily Momentum Screener With Alerts - Newser
Cyclacel Pharmaceuticals Inc. recovery potential after sell offWeekly Gain Forecast with Momentum Indicators - Newser
Full technical analysis of Cyclacel Pharmaceuticals Inc. stockProven Trading System with Consistent Gains - Newser
What the charts say about Cyclacel Pharmaceuticals Inc. todayConservative Asset Allocation Risk Analysis - Newser
Why Cyclacel Pharmaceuticals Inc. stock attracts strong analyst attentionReal-Time Entry Signals for Top Stocks - Newser
Cyclacel Pharmaceuticals Inc (CYCC) 財務データ
収益
当期純利益
現金流量
EPS
Cyclacel Pharmaceuticals Inc (CYCC) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lazar David E. | Interim CEO |
Feb 26 '25 |
Sale |
0.03 |
194,628,820 |
5,507,996 |
0 |
0.41%
0.88%
大文字化:
|
ボリューム (24 時間):